FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis

Zhang, Yixiao; Zhu, Xudong; Qiao, Xinbo; Sun, Lisha; Tian, Ye; Yang, Yongliang; Zhao, Yuhong; Liu, Caigang

doi:10.7150/ijms.48971



Theranostics

International Journal of Biological Sciences

Nanotheranostics

Journal of Cancer

Journal of Genomics

Global reach, higher impact

Full Text | PDF

Int J Med Sci 2020; 17(17):2819-2825. doi:10.7150/ijms.48971 This issue Cite

Research Paper

FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis

Yixiao Zhang¹, Xudong Zhu¹, Xinbo Qiao¹, Lisha Sun¹, Ye Tian^1,2, Yongliang Yang³, Yuhong Zhao⁴, Caigang Liu^1✉

1. Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.
2. College of Medicine and Biological Information Engineering, Northeastern University, Shenyang, Liaoning Province, 110169, China.
3. Center for Molecular Medicine, School of Life Science and Biotechnology, Dalian University of Technology, Dalian, Liaoning Province, 116023, China.
4. Department of Clinical Epidemiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, 110004, China.

Citation:

Zhang Y, Zhu X, Qiao X, Sun L, Tian Y, Yang Y, Zhao Y, Liu C. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. Int J Med Sci 2020; 17(17):2819-2825. doi:10.7150/ijms.48971. https://www.medsci.org/v17p2819.htm

Other styles

Abstract

Purpose: To characterize the role of fibrous sheath interacting protein 2 (FSIP2) in the survival outcomes and prognosis of clear cell renal cell carcinoma (ccRCC) patients, which is currently not well understood.

Methods: The Oncomine and CCLE databases were used to investigate the differential expression of FSIP2 in ccRCC versus other cancer types. Levels of FSIP2 in 85 ccRCC patients were assessed by immunohistochemical analysis; clinicopathological features related to FSIP2 expression were examined in these patients finally, disease-free survival and overall survival were estimated by survival analysis to elucidate the impact of FSIP2 expression in ccRCC patients.

Results: Analysis using the Oncomine database revealed significant upregulation of the FSIP2 gene in papillary RCC, compared to that in normal tissues. Additionally, FSIP2 expression was found to be significantly associated with abnormal platelet count, positive distant metastasis, and death as the incidence of distant metastasis and death were higher in patients with FSIP2 expression compared to those without FSIP2 expression. Survival analysis revealed that FSIP2 expression was significantly related to shorter disease-free survival and overall survival. Meanwhile, patients with FSIP2 expression had worse prognosis than those without FSIP2 expression.

Conclusions: FSIP2 expression is associated with poor survival outcomes and poor prognosis in ccRCC patients. FSIP2 may therefore serve as a potential predictive biomarker of ccRCC prognosis.

Keywords: FSIP2, ccRCC, prognosis, predictive biomarker

Citation styles

APA

Zhang, Y., Zhu, X., Qiao, X., Sun, L., Tian, Y., Yang, Y., Zhao, Y., Liu, C. (2020). FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. International Journal of Medical Sciences, 17(17), 2819-2825. https://doi.org/10.7150/ijms.48971.

ACS

Zhang, Y.; Zhu, X.; Qiao, X.; Sun, L.; Tian, Y.; Yang, Y.; Zhao, Y.; Liu, C. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. Int. J. Med. Sci. 2020, 17 (17), 2819-2825. DOI: 10.7150/ijms.48971.

NLM

CSE

Zhang Y, Zhu X, Qiao X, Sun L, Tian Y, Yang Y, Zhao Y, Liu C. 2020. FSIP2 can serve as a predictive biomarker for Clear Cell Renal Cell Carcinoma prognosis. Int J Med Sci. 17(17):2819-2825.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.